Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)

v3.20.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Common Stock Dividend Payable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 552 $ 19,124,600 $ (1,800,000)   $ (7,624,134) $ 9,701,018
Balance, shares at Dec. 31, 2018 5,525,128          
Stock-based compensation 58,559   58,559
Payments made directly by investor for clinical trial costs 115,000   115,000
Net loss   (750,832) (750,832)
Balance at Mar. 31, 2019 $ 552 19,183,159 (1,685,000)   (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 5,525,128          
Balance at Dec. 31, 2018 $ 552 19,124,600 (1,800,000)   (7,624,134) 9,701,018
Balance, shares at Dec. 31, 2018 5,525,128          
Net loss           (2,583,433)
Balance at Sep. 30, 2019 $ 549 18,877,697   (10,207,567) 8,670,679
Balance, shares at Sep. 30, 2019 5,486,595          
Balance at Mar. 31, 2019 $ 552 19,183,159 (1,685,000)   (8,374,966) 9,123,745
Balance, shares at Mar. 31, 2019 5,525,128          
Stock-based compensation 66,476   66,476
Payments made directly by investor for clinical trial costs 280,927   280,927
Net loss   (969,077) (969,077)
Balance at Jun. 30, 2019 $ 552 19,249,635 (1,404,073)   (9,344,043) 8,502,071
Balance, shares at Jun. 30, 2019 5,525,128          
Stock-based compensation 269,129   269,129
Conversion of Senior convertible notes for common stock and stock purchase warrants $ 2 258,928   258,930
Conversion of Senior convertible notes for common stock and stock purchase warrants, shares 18,107          
Payments/reimbursements made by investor for clinical trial costs 504,073   504,073
Pledged shares of common stock forfeited upon revised agreement with clinical trial investor $ (5) (899,995) 900,000  
Pledged shares of common stock forfeited upon revised agreement with clinical trial investor, shares (56,640)          
Net loss   (863,524) (863,524)
Balance at Sep. 30, 2019 $ 549 18,877,697   (10,207,567) 8,670,679
Balance, shares at Sep. 30, 2019 5,486,595          
Balance at Dec. 31, 2019 $ 549 18,994,008   $ 3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,595          
Stock-based compensation 98,663   98,663
Transaction costs related to anticipated 2020 offering (2,806)   (2,806)
Net loss   (874,336) (874,336)
Balance at Mar. 31, 2020 $ 549 19,089,865   3 (11,856,346) 7,234,071
Balance, shares at Mar. 31, 2020 5,486,595          
Balance at Dec. 31, 2019 $ 549 18,994,008   3 (10,982,010) 8,012,550
Balance, shares at Dec. 31, 2019 5,486,595          
Net loss           (4,679,035)
Balance at Sep. 30, 2020 $ 577 21,187,697   (15,661,045) 5,527,229
Balance, shares at Sep. 30, 2020 5,765,566          
Balance at Mar. 31, 2020 $ 549 19,089,865   3 (11,856,346) 7,234,071
Balance, shares at Mar. 31, 2020 5,486,595          
Stock-based compensation 93,869   93,869
Transaction costs related to anticipated 2020 offering (1,506)   (1,506)
Stock dividend distributed due to full-ratchet anti-dilution adjustment $ 3   (3)
Stock dividend distributed due to full-ratchet anti-dilution adjustment, shares 28,971          
Net loss   (733,414) (733,414)
Balance at Jun. 30, 2020 $ 552 19,182,228   (12,589,760) 6,593,020
Balance, shares at Jun. 30, 2020 5,515,566          
Stock-based compensation 164,507   164,507
Transaction costs related to anticipated 2020 offering (356,416)   (356,416)
Shares issued in connection with Yuhan license agreement $ 25 1,999,975   2,000,000
Shares issued in connection with Yuhan license agreement, shares 250,000          
Fair value of warrants issued in the sale of our 2019 Senior Notes 197,403   197,403
Net loss   (3,071,285) (3,071,285)
Balance at Sep. 30, 2020 $ 577 $ 21,187,697   $ (15,661,045) $ 5,527,229
Balance, shares at Sep. 30, 2020 5,765,566